IGC Pharma (IGC Pharma) Operating Cash Flow per Share : $-0.11 (TTM As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is IGC Pharma Operating Cash Flow per Share?

IGC Pharma's operating cash flow per share for the three months ended in Dec. 2023 was $-0.03. IGC Pharma's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.11.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 15.20% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -14.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for IGC Pharma's Operating Cash Flow per Share or its related term are showing as below:

IGC' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -200 Med: 15.2 Max: 53.4
Current: 15.2

During the past 13 years, IGC Pharma's highest 3-Year average Operating Cash Flow per Share Growth Rate was 53.40% per year. The lowest was -200.00% per year. And the median was 15.20% per year.

IGC's 3-Year OCF Growth Rate is ranked better than
61.83% of 1234 companies
in the Biotechnology industry
Industry Median: 3.5 vs IGC: 15.20

IGC Pharma Operating Cash Flow per Share Historical Data

The historical data trend for IGC Pharma's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma Operating Cash Flow per Share Chart

IGC Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.09

-0.22

-0.26

-0.15

-0.13

IGC Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.03	-0.03	-0.03	-0.03	-0.03

Competitive Comparison of IGC Pharma's Operating Cash Flow per Share

For the Biotechnology subindustry, IGC Pharma's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IGC Pharma's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where IGC Pharma's Price-to-Operating-Cash-Flow falls into.

IGC Pharma Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

IGC Pharma's Operating Cash Flow per Share for the fiscal year that ended in Mar. 2023 is calculated as

Operating Cash Flow per Share (A: Mar. 2023 )	=	Cash Flow from Operations (A: Mar. 2023 )	/	Shares Outstanding (Diluted Average) (A: Mar. 2023 )
	=	-7.047	/	52.576
	=	-0.13

IGC Pharma's Operating Cash Flow per Share for the quarter that ended in Mar. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	-1.587	/	63.725
	=	-0.02

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.11

IGC Pharma Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of IGC Pharma's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

IGC Pharma (IGC Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (AMEX:IGC) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

IGS1:Germany

Address

10224 Falls Road, Potomac, MD, USA, 20854

Website

https://www.igcinc.us

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Executives

James P Moran	director	914 SPRING HILL ROAD, MCLEAN VA 22102
John Edward Lynch	director	14 PARK AVENUE, REHOBOTH BEACH DE 19971
Richard K Prins	director
Ram Mukunda	director, officer: Exec. Chairman & CEO
Claudia Grimaldi	officer: Vice president and PFO	PO BOX 60642, POTOMAC MD 20859
Rohit Goel	officer: Manager & PAO	PO BOX 60642, POTOMAC MD 20859
John Cherin	officer: CFO, Treasurer and PAO	662 LIVE OAK DRIVE, MCLEAN VA 22101
Shu Kwong Ngai	director, officer: Interim CFO	4336 MONTGOMERY AVENUE, BETHESDA MD 20814
Ranga C Krishna	director	330 THORNTON ROAD, ENGLEWOOD X1 07631
Sudhakar V Shenoy	director	10411 MOTOR CITY DRIVE, BETHESDA MD 20817
Suhail Nathani	director	INDIA GLOBALIZATION CAPITAL, INC., 4336 MONTGOMERY AVE., BETHESDA MD 20814
Nisswa Acquisition Master Fund Ltd.	10 percent owner	C/O MAPLES CORPORATE SVCS LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Smith Edward B Iii	10 percent owner	C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
Ag Ubs	10 percent owner	600 WASHINGTON BLVD., STAMFORD CT 06901
Pine River Master Fund Ltd.	10 percent owner	C/O PINE RIVER CAPITAL MANAGEMENT L.P., 601 CARLSON PARKWAY, 7TH FLOOR, MINNETONKA MN 55305